Qiagen and Celera establish distribution agreement for respiratory pathogen panel
Qiagen and Celera have announced an agreement under which Qiagen will distribute a Celera molecular multiplex assay. The assay is the next generation version of Qiagen’s ResPlex II assay for detection of respiratory pathogens. Multiplex assays allow testing for a multiple number of different pathogens in a single run.
Under the terms of the agreement, Qiagen has the exclusive worldwide rights to distribute this multiplex test kit, which will be manufactured by Celera. The ResPlex assay detects 19 different pathogens associated with respiratory infections and is designed for use with LiquiChip (Luminex) 100 and 200 instrument platforms.
The new ResPlex kits will be available through Qiagen’s existing sales channels. The new test will be submitted for regulatory approval in the United States and Europe.
L'Oréal-UNESCO For Women In Science Fellows announced for ANZ
This year's program honours four women who are reshaping what leadership in research looks...
Peter Beattie appointed Chair of Brandon BioCatalyst
Brandon BioCatalyst has announced new board appointments to continue the scaling of Australian...
Virologist receives GSK Award for AI-based disease detection
Professor Edward Holmes has received the 2025 GSK Award for Research Excellence for his use of...
